F M Investments LLC Purchases 13,571 Shares of Johnson & Johnson (NYSE:JNJ)

F M Investments LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 14.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 105,437 shares of the company's stock after purchasing an additional 13,571 shares during the period. F M Investments LLC's holdings in Johnson & Johnson were worth $15,248,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock worth $33,666,460,000 after purchasing an additional 1,772,706 shares during the period. Geode Capital Management LLC grew its position in Johnson & Johnson by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after buying an additional 1,561,036 shares in the last quarter. Norges Bank bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $4,390,037,000. Wellington Management Group LLP increased its position in shares of Johnson & Johnson by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock worth $3,522,447,000 after purchasing an additional 431,205 shares during the period. Finally, Invesco Ltd. grew its stake in Johnson & Johnson by 6.5% during the fourth quarter. Invesco Ltd. now owns 19,126,079 shares of the company's stock worth $2,766,014,000 after buying an additional 1,171,975 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on JNJ shares. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Wells Fargo & Company lowered their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Leerink Partners decreased their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Finally, Raymond James reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $171.50.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded up $1.85 during midday trading on Monday, hitting $153.58. The company's stock had a trading volume of 3,687,113 shares, compared to its average volume of 7,937,407. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The firm has a market capitalization of $370.10 billion, a price-to-earnings ratio of 23.09, a P/E/G ratio of 2.56 and a beta of 0.49. The stock has a fifty day moving average price of $159.40 and a 200 day moving average price of $155.17.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.29 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Insider Activity

In related news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.